CXI Healthcare to Acquire 100% of Fujian Yong Shenghuo Li from Subsidiary at Zero Cost for Governance Restructuring
CXI Healthcare Technology Group Limited announced on July 15, 2026, its board resolution to acquire 100% equity of Fujian Yong Shenghuo Li Biological Engineering Co., Ltd. from its subsidiary Zhejiang Zhengcheng Health Technology Group Co., Ltd. at zero consideration.
The acquisition is expected to close on August 31, 2026. An independent valuation by Induk Accounting Corporation using the DCF method assessed the target's equity value between 1,423,879 thousand CNY and 2,008,006 thousand CNY, but the transaction is a gratuitous transfer with no cash outflow.
This restructuring aims to improve management efficiency and decision-making within the consolidated group. Since no new shares are issued and no dilution occurs, existing shareholder value is unaffected.
The target company operates in health supplements and tea distribution. Its recent three-year average revenue was approximately 32.7 billion KRW and net income 13.9 billion KRW, but it recorded an operating loss in Q1 2026, indicating earnings volatility.
No special financing is needed for this zero-cost acquisition. The company's retained earnings have been increasing, but no separate dividend policy disclosure has been made.
[AI Summary]This intra-group restructuring involves no cash outlay or dilution, making it neutral for shareholders. However, the target's assessed value of up to 313 billion KRW contrasts with the zero transaction price, which may diverge from market expectations.
KOSDAQ Filing Information
Report on Major Matters (Decision to Acquire Stocks and Investment Securities of Other Corporation)
Company: CXI Healthcare Technology Group (900120)
Submission: CXI Healthcare Technology Group Limited